The biopharmaceutical corporation has today given a clear signal of intent that it is on the pathway to convert its rich pipeline of plasma derived therapeutics, into a multi-centre production operation. The focus for 2015 and 2016 is very much on gaining approvals for multiple candidates which are currently in or imminently due to enter the clinical phase, and we expect no slow-down of development activity in the foreseeable future. However what we do expect is for manufacturing and sales of
19 May 2015
Prometic expands production capacity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prometic expands production capacity
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
19 May 2015 -
Author:
Derren Nathan -
Pages:
6
The biopharmaceutical corporation has today given a clear signal of intent that it is on the pathway to convert its rich pipeline of plasma derived therapeutics, into a multi-centre production operation. The focus for 2015 and 2016 is very much on gaining approvals for multiple candidates which are currently in or imminently due to enter the clinical phase, and we expect no slow-down of development activity in the foreseeable future. However what we do expect is for manufacturing and sales of